The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
复制标题
DOI：
10.1136/jitc-2019-000155
复制
发表时间：
2020-01-01
影响因子：
10.9
通讯作者：
Bifulco, Carlo B.
中科院分区：
文献类型：
--
作者：
Taube, Janis M.;Akturk, Guray;Bifulco, Carlo B.
目的免疫系统与肿瘤细胞之间的相互作用是肿瘤预后和治疗的重要特征。多重免疫组织化学(MIHC)和多重免疫荧光(MIF)分析是一种新兴的技术，可以用来帮助定量免疫细胞亚群，它们的功能状态，以及它们在肿瘤微环境中的空间排列。方法癌症免疫治疗学会(SITC)召集了一个由来自学术中心的病理学家和实验室负责人以及来自制药和诊断公司的专家组成的工作组来制定最佳实践指南，以优化和验证MIHC/MIF分析方法。结果典型的结果和MIHC/MIF方法的优缺点，如多重显色IHC，多重免疫组织化学连续染色，MIF(包括多光谱方法)，基于组织的质谱学，结论IHC/MIF技术正在成为生物标志物研究的标准工具，并有可能在不久的将来进入常规临床实践。仔细的分析优化和验证将有助于确保不同实验室以及潜在的MIHC/MIF平台的输出是稳健的和可比较的。MIHC/MIF输出的定量图像分析和数据管理考虑因素将在本工作队的补充手稿中阐述。
ObjectivesThe interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging technologies that can be used to help quantify immune cell subsets, their functional state, and their spatial arrangement within the tumor microenvironment.MethodsThe Society for Immunotherapy of Cancer (SITC) convened a task force of pathologists and laboratory leaders from academic centers as well as experts from pharmaceutical and diagnostic companies to develop best practice guidelines for the optimization and validation of mIHC/mIF assays across platforms.ResultsRepresentative outputs and the advantages and disadvantages of mIHC/mIF approaches, such as multiplexed chromogenic IHC, multiplexed immunohistochemical consecutive staining on single slide, mIF (including multispectral approaches), tissue-based mass spectrometry, and digital spatial profiling are discussed.ConclusionsmIHC/mIF technologies are becoming standard tools for biomarker studies and are likely to enter routine clinical practice in the near future. Careful assay optimization and validation will help ensure outputs are robust and comparable across laboratories as well as potentially across mIHC/mIF platforms. Quantitative image analysis of mIHC/mIF output and data management considerations will be addressed in a complementary manuscript from this task force.